Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't ...
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...
Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...
Its financials aren't in bad shape, and while the stock has been struggling, now could make a great time to load up on it. Here are three reasons why Pfizer could prove to be a steal of a deal ...
In this article, we are going to take a look at where Pfizer Inc. (NYSE ... and we’re going to make up a lot of territory,” Trump said. On February 21, Jared Holz, Mizuho Securities America ...
Shrewd investors know that bear markets open up great opportunities ... But at its current levels, Pfizer might be a steal for long-term investors. Here's why. It's no secret why Pfizer has ...
In this article, we are going to take a look at where Pfizer Inc. (NYSE ... and the situation hasn’t come up much on earnings calls over this quarter.” We sifted through stock screeners, online ...
Citi analyst Geoff Meacham keeps a Neutral rating on Pfizer (PFE) with a $27 price target after the Wall Street Journal reported that U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback